A 67-year-old patient presenting with esophageal cancer was treated today at the Paul Scherrer Institute PSI with a form of radiation provided by protons, i.e. positively charged particles.
With its ex-Novartis cancer drug near the finish line, Adlai Nortye raises $97.5M in Nasdaq debut
The Nasdaq is welcoming another company hustling along a late-stage drug, with Adlai Nortye raising $97.5 million from an IPO and a concurrent private placement.